Home > News

Chiesi enters in an exclusive global license agreement with TiumBio to develop innovative molecules...

TiumBio grants Chiesi global rights to develop small molecules targeting transforming growth factor beta (TGF-β) signaling in respiratory indications This agreement expands Chiesi’s...

1/13

StartUp Health raises 31 million dollars from the Chiesi Group and a prominent group of other large...

2/13

Chiesi signs a deal with StartUp Health: first investment in the digital area

3/13

ARCHIVE NEWS

Chiesi supports The Third Day exhibition, dedicated to the relationship between man and nature

17 Aprile 2018

Global Corporate Development : opening of new offices in Boston

16 Marzo 2018

Chiesi Digital Transformation - Digital Safari Workshop with David Orban

24 Gennaio 2018

Chiesi enters into an Exclusive ex-US Partnership with Protalix BioTherapeutics for the Development and Commercialization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease

20 Ottobre 2017

Chiesi certified Top Employer also for 2017

13 Febbraio 2017

Chiesi is Top Employer again!

15 Febbraio 2016

Alberto, Paolo and Andrea Chiesi winners of the “Entrepreneur of the year 2015” Award

30 Novembre 2015

Special Mention to Holoclar at the Italian Galeno Award

26 Novembre 2015

COPD indication for Foster pMDI

21 Marzo 2014

Double-digit growth and internal expansion for the Chiesi Group

14 Marzo 2014

Vat 01513360345
Payed Up Capital: Euro 75.000.000
Companies Register Office - Parma N.15739
REA: 159271

CHIESI ON THE WEB